Biosimilar spat erupts again in Europe
This article was originally published in Scrip
The European biotechnology industry body EuropaBio says that the labeling of biosimilar medicines should make clear whether the data used for their approval were generated for the biosimilar or its reference product, and should include information on the reasons for any extrapolation of indications.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.